Postscripts Rx

Digital companions are revolutionizing the post-prescription landscape, turning traditional patient support upside down. Cathy Zaremba, Senior Director of Marketing at Medisafe, reveals how personalized, data-driven platforms are transforming medication adherence and patient outcomes through just-in-time interventions.

The statistics are sobering: only 50% of patients with chronic conditions adhere to treatments long-term, costing the US healthcare system an estimated $300 billion annually. Meanwhile, 71% of patients crave digital experiences that align with their personal habits. Medisafe addresses this gap with sophisticated technology that meets patients exactly where they are in their therapeutic journey.

What makes digital companions effective isn't just technology—it's empathy. "Information alone doesn't change behavior," Zaremba explains. Through intelligent design and personalized support, Medisafe users stay engaged for an average of 17 months (compared to typical 30-day drop-offs), with 70% interacting at least once daily. Simple empathetic language has shown to improve engagement by over 40% during challenging therapy points, proving that patients "aren't just engaging with tech, they're engaging with trust."

The conversation explores Medisafe's exciting innovations, including Via—their voice intelligent agent combining conversational AI with behavioral data to create natural, supportive interactions. Zaremba also shares how Medisafe captures over 50 billion data points globally, providing pharma companies with unprecedented visibility into patient behavior patterns that were previously invisible through traditional reporting.

As healthcare continues evolving toward value-based care, Medisafe is expanding AI-powered predictive adherence tools and integrations across health ecosystems. The message is clear: the future of patient support isn't just about prescriptions written—it's about prescriptions completed and lives improved.

Listen now to discover how digital companions are becoming the critical difference-maker in patient success stories worldwide. Follow Postscript for more insights at the intersection of pharma, technology, and patient impact.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The pharmaceutical landscape is shifting dramatically beneath our feet. With the US government recently demanding drug price reductions of up to 60% from major pharma companies or face potential reimbursement restrictions, the industry faces what CNBC calls "one of the most dramatic reshufflings of commercial pharma strategy in decades."

This perfect storm – innovation surging while margins tighten – creates urgent questions for pharma marketers, patient support teams, and innovation leaders. How do you maintain growth when prices fall? The answer increasingly lies in what happens after the prescription is written. When medication non-adherence wastes nearly $300 billion annually in US healthcare spending, closing that gap even incrementally represents massive opportunity.

Digital companions that support patients throughout their medication journey are proving their value through hard data. Users experience 17% better adherence across therapeutic areas and 37% improved refill persistence over six months. Some brands achieve up to 4:1 ROI through these platforms. These aren't vanity metrics – they directly impact market share, script lift, and patient outcomes.

As the competitive landscape evolves, three key metrics are becoming central to pharma success: adherence impact on lifetime value, conversion rates from triggered interventions at critical therapy points, and the cost-benefit analysis of human support versus digital automation. Brands that excel in these areas protect revenue even as prices fall.

Looking ahead, digital support isn't optional – it's a competitive necessity. The strongest pharmaceutical brands will be those that build loyalty through patient relationships, demonstrate measurable outcomes, and partner with platforms that scale engagement across therapeutic areas. When every script counts more than ever, how are you measuring what happens after the first prescription?

Ready to discover how digital companions can protect your brand's market share in these challenging times? Subscribe to Postscripts for more insights on innovations driving better outcomes for patients and pharma alike.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The healthcare landscape is being reshaped by a powerful new tool: AI voice agents. These conversational companions are addressing one of healthcare's most persistent challenges – medication non-adherence, which affects 50% of patients with chronic conditions and costs the US healthcare system over $300 billion annually.

Unlike traditional digital solutions that require technical proficiency, AI voice agents leverage natural conversation to provide timely medication reminders, education, and encouragement. For elderly patients, the visually impaired, or those with limited digital literacy, these voice-first interactions remove barriers to consistent medication management. Platforms like Medisafe Via exemplify this approach, offering multimodal support through voice-guided tracking that enhances accessibility while maintaining human-centered care.

The benefits extend throughout the healthcare ecosystem. Physicians currently spend over 15 hours weekly on prior authorizations alone – a leading contributor to burnout. AI voice agents embedded in EHR platforms can automate intake processes, verify insurance, and support authorization workflows, allowing clinicians to focus on patient care rather than paperwork. Mayo Clinic has already demonstrated remarkable success, with their AI voice program serving 450,000+ patients and achieving an 80% response rate while enabling care teams to prioritize those truly needing human intervention.

For underserved populations facing language barriers or limited technology access, voice agents provide multilingual support without requiring smartphones. For pharmaceutical companies, these technologies offer new channels for delivering personalized, brand-specific messaging beyond traditional representatives or digital advertisements. The micro-interactions facilitated by voice agents compound over time, building trust and driving deeper engagement with treatments.

As we look ahead, voice interfaces will increasingly become the foundation of patient experiences – not replacing human connection, but elevating it by making healthcare more scalable, proactive, and patient-centered. Have you considered how voice automation might transform your patient support strategy? Subscribe to Postscripts for more insights at the intersection of pharma technology and patient impact.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

The healthcare technology landscape is undergoing a profound transformation with a White House-led initiative dubbed "Make Health Technology Great Again" that aims to create a streamlined approach to health data sharing through a nationwide tracking system.

• Accelerated interoperability in health data can transform brand strategies by enabling precision targeting and improved patient engagement
• Innovation teams can fast-track development of scalable digital health solutions with fewer technical or regulatory hurdles
• Patient access and support teams can shift from reactive to proactive approaches with real-time insurance verification and smart routing
• Patients benefit through less paperwork, more personalized support, faster access to treatments, and better engagement leading to improved outcomes
• Digital companions like Medisafe can deliver contextualized interventions that work around the clock to support patients' therapeutic journeys
• The initiative addresses significant gaps in current healthcare delivery, including the 38% of prescriptions that go unfilled in the first 30 days

Thanks for joining us on Postscripts. If you found this conversation valuable, follow or subscribe for more insights at the intersection of pharma technology and patient impact at postscriptspodcast.com.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Digital health expectations are becoming the new baseline in healthcare as patients increasingly expect the same level of convenience they experience in other aspects of their digital lives. The disconnect between modern consumer expectations and traditional healthcare delivery isn't just frustrating—it can jeopardize treatment outcomes and patient satisfaction.

• Over 70% of patients wish healthcare interactions were as easy as online shopping or digital banking
• 43% of patients would switch to a different pharma brand for better digital support
• Digital platforms provide personalized treatment journeys, timely nudges, and engaging support
• Digital tools like voice interactive agents can deliver personalized interventions at scale
• Data-powered platforms can identify patient behavior patterns and fill gaps in adherence
• One pharma company saw a 20% lift in 90-day retention using digital patient support
• U.S. policy changes like the Inflation Reduction Act are increasing pressure for better outcomes
• Digital solutions enhance rather than replace human care by allowing support teams to focus on high-need patients
• Future success for pharma brands lies in scaling proven digital solutions across portfolios

Follow or subscribe to Postscripts for more insights on the intersection of pharma, technology, and patient impact.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

What defines truly effective digital health technology in today's healthcare landscape? According to Brian Carr, SVP of Marketing at Medisafe, the answer is refreshingly straightforward: patient engagement. 

When seven out of ten users access your platform daily—outperforming even social media giants like Facebook—you know you've created something that genuinely resonates with patients. Medisafe's journey began with a personal crisis when the founder's father accidentally double-dosed on insulin after forgetting his previous dose. This pivotal moment established the company's unwavering patient-first philosophy that continues to guide their innovation today.

The secret behind Medisafe's remarkable engagement metrics lies in their proprietary database built over twelve years, containing billions of anonymized patient interactions. This rich foundation powers their Just-In-Time Interventions (JITI), delivering personalized support precisely when patients need it most. Unlike many emerging AI solutions dependent on third-party datasets, Medisafe's technology draws from real-world patient behaviors to create truly personalized experiences.

Beyond medication reminders, Medisafe bridges critical gaps in the healthcare ecosystem. Patients can share adherence reports with providers, display their complete medication lists during emergency visits, and access digital copay cards—all from their smartphones. Meanwhile, pharmaceutical partners gain unprecedented visibility into patient behaviors, seeing how their medications perform alongside others in real-world settings, with insights available not just quarterly but hour-by-hour.

Looking toward healthcare's future, Carr envisions AI-powered voice agents and deeper integration across care settings, transforming how patients experience their treatment journeys. The leaders who will thrive in this evolving landscape will combine curiosity and openness with decisive action, recognizing that exceptional technology always begins with addressing genuine patient needs.

Subscribe to PostscriptsRx to continue exploring the innovations and visionaries shaping the future of patient care. How might these advancements transform your approach to healthcare delivery?

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

A seismic shift may be approaching the pharmaceutical industry with US administration statements suggesting pharmaceutical import tariffs could reach a staggering 250 percent. This isn't just another policy headline – it represents a potential transformation of drug pricing, patient access, and brand performance that demands strategic preparation.

With approximately 80% of active pharmaceutical ingredients in US medications coming from overseas, these tariffs could trigger multiple cascading effects. Research shows even modest price increases significantly impact patient adherence – a 25% price hike leads to a 17% drop in medication compliance. When monthly costs exceed $100, patient sensitivity to out-of-pocket expenses spikes dramatically, potentially driving switches from original medications to domestically produced alternatives perceived as more affordable.

The ripple effects extend throughout healthcare ecosystems. Insurers will likely implement stricter formulary controls and prior authorization requirements, creating access barriers that frustrate both patients and providers. Pharmaceutical companies may rationalize portfolios, quietly sunsetting underperforming drugs and leaving patient populations with diminished support. Retail pharmacies, already dedicating substantial time to insurance issues, will shoulder the burden of explaining price increases and coverage challenges to confused patients.

Digital patient engagement platforms emerge as critical tools in this volatile landscape. These solutions can identify cost barriers early, support patients through complex authorization processes, maintain meaningful engagement even for sunset brands, and reduce administrative burdens on healthcare providers. As some manufacturers shift toward domestic production – potentially delaying launches by years despite regulatory streamlining efforts – digital engagement becomes essential for maintaining therapeutic continuity and brand loyalty.

What's your contingency plan for when these tariffs hit? Share your thoughts with us at postscriptspodcast.com and subscribe to hear from our upcoming guests navigating these uncharted waters.

PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.